Johnson & Johnson has moved another major multiple myeloma therapy toward substantially earlier European use after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended expanding Tecvayli monotherapy to adults with relapsed or refractory multiple myeloma who have received at least one prior treatment. The September 18 recommendation is supported by Phase 3 MajesTEC-9 data showing teclistamab reduced the risk of disease progression or death by 71% and the risk of death by 40% compared with established combination therapies.
The regulatory step matters because Tecvayli originally entered Europe in 2022 for patients who had already received at least three prior therapies. Moving an off-the-shelf BCMA-directed bispecific antibody from heavily pretreated disease toward the first relapse greatly enlarges the potential population and gives Johnson & Johnson another route for embedding T-cell-engaging therapy much earlier in the multiple myeloma treatment sequence. More than 30,700 patients worldwide had already been treated with Tecvayli as of July 2026, according to company data.
The latest recommendation is also distinct from the European Commission’s August approval of Tecvayli in combination with daratumumab after at least one prior therapy. If the European Commission follows the new CHMP opinion, physicians could potentially have both a Tecvayli-based doublet and Tecvayli monotherapy available in earlier relapsed disease, giving Johnson & Johnson considerable flexibility in positioning the drug according to patient fitness, treatment history and tolerability.
How strong were the Phase 3 MajesTEC-9 results behind the European recommendation?
MajesTEC-9 compared Tecvayli monotherapy with physician-selected standard regimens consisting of pomalidomide, bortezomib and dexamethasone or carfilzomib and dexamethasone. Patients had received between one and three previous treatment lines, including lenalidomide and an anti-CD38 monoclonal antibody, placing the study in a difficult population where resistance to major established drug classes had already emerged.
The progression-free survival result was substantial. Tecvayli produced a hazard ratio of 0.29, translating into a 71% reduction in the relative risk of progression or death compared with standard care. Overall survival also significantly favored Tecvayli, with a hazard ratio of 0.60 representing a 40% reduction in death risk. Both findings crossed conventional statistical significance thresholds, giving Johnson & Johnson evidence not only that the therapy delayed progression but that patients lived longer.
Depth of response provided another important signal. Approximately 65.9% of patients receiving Tecvayli achieved a complete response or better compared with only 16.8% receiving the comparator regimens. That difference matters in multiple myeloma because deeper responses are increasingly used to identify therapies capable of producing prolonged disease control rather than transient tumor reduction.
The data therefore provide a stronger commercial argument than an indication expansion based only on response rate. Johnson & Johnson can point to progression-free survival, overall survival and deep-response advantages in the same randomized Phase 3 program.
Why does moving Tecvayli to first relapse dramatically change its commercial opportunity?
Multiple myeloma remains incurable for most patients, but survival has improved substantially as treatment has expanded across proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, CAR-T therapies and bispecific antibodies. The problem is attrition. Patients become less likely to reach each subsequent treatment line as disease progresses, complications accumulate and performance status deteriorates.
That means a medicine used after one previous therapy can address a materially larger population than the same drug reserved until after three or four regimens have failed. Johnson & Johnson is therefore moving Tecvayli upstream before patients become as heavily treated and before immune function deteriorates further.
Europe recorded more than 35,000 new multiple myeloma diagnoses in 2024 and more than 21,900 deaths, according to estimates cited by Johnson & Johnson. Relapse is common, and successive remissions generally become shorter as resistance develops.
Earlier use could also increase treatment duration. Patients in MajesTEC-9 remained on Tecvayli for a median 13.1 months compared with 7.0 months for standard treatment. Longer duration reflects disease control but also creates additional commercial value because Tecvayli is administered repeatedly rather than as a one-time therapy.
The result is classic pharmaceutical lifecycle expansion: the same molecule moves into a substantially larger treatment population and may remain in use longer.
Could Tecvayli compete with Johnson & Johnson’s own Darzalex and Carvykti franchises?
Johnson & Johnson now possesses several major myeloma franchises that increasingly overlap across treatment lines. Darzalex remains a foundational anti-CD38 therapy, Carvykti is a BCMA-directed CAR-T treatment, Tecvayli targets BCMA through an off-the-shelf bispecific format and Talvey targets GPRC5D.
Rather than avoiding internal competition, Johnson & Johnson appears to be building a portfolio capable of surrounding the disease at different stages. Some patients may be candidates for cellular therapy, others may need immediately available bispecific treatment, and still others may benefit from combination approaches involving Darzalex.
The commercial scale of that portfolio is already considerable. Darzalex generated $4.21 billion in worldwide second-quarter 2026 sales, up 18.9% year over year, while Carvykti revenue increased 49.4% to $657 million. Tecvayli sales reached $260 million, rising 56.5%, and Talvey generated $174 million, up 63.3%. Johnson & Johnson’s total oncology revenue reached $7.41 billion for the quarter, increasing 17.3%.
Those numbers illustrate why moving Tecvayli into second line matters even though the product is still much smaller than Darzalex. The franchise is growing from a relatively low base while regulatory expansion gives it access to patients earlier in their treatment journey.
Johnson & Johnson reported that second-quarter Tecvayli growth was being supported by earlier-line uptake and increasing use in community treatment settings. Wider second-line monotherapy access in Europe could reinforce that trajectory if clinicians see value in an off-the-shelf immune therapy that does not require CAR-T manufacturing.
How does Tecvayli compare with CAR-T therapy from an operational perspective?
BCMA-directed CAR-T therapy can produce deep and durable responses but requires patient-cell collection, manufacturing, lymphodepleting chemotherapy and treatment through specialized centers. That manufacturing interval can be problematic for patients whose disease is progressing rapidly.
Tecvayli is an off-the-shelf bispecific antibody. It binds BCMA on myeloma cells and CD3 on T cells, redirecting the patient’s immune cells toward the cancer without requiring an individualized cellular product to be manufactured.
That availability can make bispecific treatment easier to scale across a larger patient population, particularly as hospitals become more familiar with cytokine release syndrome management and step-up dosing. Johnson & Johnson is also trying to expand treatment beyond large academic institutions, which could prove critical if Tecvayli becomes routinely used after first relapse.
However, off-the-shelf convenience should not be confused with low treatment complexity. Bispecific antibodies carry important infectious and immune-related risks, and the MajesTEC-9 safety results show why earlier adoption still requires careful patient management.
What safety trade-off accompanies Tecvayli’s large efficacy advantage?
Grade 3 or 4 adverse events occurred in 84.9% of Tecvayli-treated patients compared with 76.3% receiving standard care. Grade 5 events, meaning fatal adverse events, occurred in 6.5% and 3.5% respectively. Johnson & Johnson reported that the overall safety profile remained consistent with previous Tecvayli experience, but the absolute rates underline the seriousness of treating relapsed multiple myeloma with immune-engaging therapy.
Infections are particularly important. Grade 3 or 4 infections occurred in 41.6% of patients receiving Tecvayli compared with 29.0% in the comparator group, although Johnson & Johnson said rates of severe infection decreased over time.
That infection burden will matter more as the therapy moves earlier. Physicians must decide whether the substantial progression-free and overall survival advantages justify prolonged immunosuppression and infection-management requirements in patients who may have several other treatment options available.
The trade-off is therefore unusually clear. Tecvayli produced much stronger disease control, but patients remained on treatment almost twice as long and experienced more severe infections. European adoption will depend partly on how clinicians balance those two realities.
Why could having both Tecvayli monotherapy and a Tecvayli-Darzalex combination matter?
Europe has already approved Tecvayli plus daratumumab after at least one previous therapy based on the Phase 3 MajesTEC-3 study. That combination delivered unusually durable results, including an 83.3% three-year overall survival rate in data supporting earlier regulatory decisions.
The latest regulatory recommendation creates a different option. Monotherapy can potentially reduce regimen complexity and avoid exposing every patient to an additional drug where the clinician believes Tecvayli alone is appropriate.
That flexibility could broaden uptake because relapsed multiple myeloma is highly heterogeneous. Age, frailty, previous anti-CD38 exposure, infection history, kidney function and disease aggressiveness can all influence treatment selection.
Commercially, Johnson & Johnson benefits in either direction. Darzalex plus Tecvayli reinforces two proprietary products simultaneously, while Tecvayli monotherapy allows the BCMA asset to compete where another combination may be undesirable.
The company is also advancing Tecvayli with Talvey, creating a dual-antigen approach targeting both BCMA and GPRC5D. Phase 3 MonumenTAL-6 topline results previously showed that the combination reduced progression or death risk by 89% and death risk by 62% compared with standard treatment, demonstrating how aggressively Johnson & Johnson is experimenting with its internal myeloma portfolio.
What does the latest myeloma progress mean for Johnson & Johnson investors?
Johnson & Johnson closed at $269.99 on September 18, down just 0.09% for the session after gaining 1.1% a day earlier. The shares remained materially higher for 2026, with recent market reporting placing the year-to-date increase at roughly 30%, although individual daily movements cannot reasonably be attributed to the Tecvayli recommendation alone.
The broader operating backdrop remains strong. Johnson & Johnson generated $25.31 billion in second-quarter sales, up 6.6%, while Innovative Medicine revenue increased 7.8% to $16.38 billion. The company raised full-year guidance and now expects reported 2026 sales of approximately $101.1 billion at the midpoint.
Tecvayli is therefore not large enough by itself to dictate Johnson & Johnson’s valuation. Its significance lies in the growth composition. The company is attempting to offset pressure on older medicines such as Stelara with newer oncology, immunology and neuroscience franchises, and second-quarter results identified Darzalex, Carvykti, Tecvayli and Rybrevant/Lazcluze among the principal oncology growth drivers.
A successful European second-line monotherapy expansion would strengthen that transition by moving one of the company’s fastest-growing oncology medicines into a larger addressable market.
What happens next for Tecvayli in Europe?
The CHMP recommendation now moves to the European Commission for a final decision. Approval would extend Tecvayli monotherapy from its existing heavily pretreated setting to adults who have received only one previous therapy, giving physicians an additional earlier-line option alongside the recently approved Tecvayli-daratumumab regimen.
Commercial execution will then become the key test. Johnson & Johnson must demonstrate that hospitals can manage infection risk, step-up dosing and immune-related complications at sufficient scale while convincing physicians that an immediately available bispecific offers advantages over competing drug combinations and CAR-T strategies.
The MajesTEC-9 result gives the company a powerful clinical argument: a 71% reduction in progression or death risk, a 40% reduction in mortality and complete responses in almost two-thirds of treated patients. The remaining question is how rapidly those numbers can move Tecvayli from a specialist late-line therapy into a routinely considered treatment at the first major relapse.
